Graft-versus-host disease A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation

UCLA Center for the Health Sciences, Los Angeles, CA; Brigham and Women’s Hospital, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Dana Farber Cancer Institute, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY; Tufts-New England Medical Center, Boston, MA; Cancer Research Center and Department of Pediatrics, University of California at San Francisco, San Francisco, CA; Rush-Presbyterian-St Luke’s Medical Center, Chicago, IL; Case Western Reserve University Hospital, Cleveland, OH; University of Utah Hospital, Salt Lake City, UT; St Joseph’s Hospital, Orange, CA; Emory University Cancer Center, Atlanta, GA; and Alpha Therapeutic Corporation, Los Angeles, CA, USA